Publication Date
12-31-2024
Journal
Human Vaccines & Immunotherapeutics
DOI
10.1080/21645515.2024.2378543
PMID
39104200
PMCID
PMC11305028
PubMedCentral® Posted Date
8-5-2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Humans, Immunotherapy, Adoptive, Hematologic Neoplasms, Receptors, Chimeric Antigen, Treatment Outcome, T-Lymphocytes, Clinical Trials as Topic, CAR-T, CAR-T efficacy, CAR-T safety, CAR-T outcomes, CAR-T real-world, chimeric antigen receptor T-cell therapy outcomes
Abstract
CAR-T cell therapy has established itself as a highly effective treatment for hematological malignancies. There are currently six commercial CAR-T products that have been FDA approved for diseases such as B-ALL, LBCL, MCL, FL, MM, and CLL/SLL. "Real-world" studies allow us to evaluate outcomes from the general population to determine their efficacy and safety compared to those who were included in the original trials. Based on several well conducted "Real-world" studies that represent diverse populations, we report that outcomes from the original trials that led to the approval of these therapies are comparable to those in practice.
Included in
Hematology Commons, Immunotherapy Commons, Medical Sciences Commons, Neoplasms Commons, Oncology Commons